Research information, not medical advice. This page summarises published evidence and registered trials so that you can look further; it does not assess your situation. Talk to your own clinician before acting on anything here. How we select and grade sources
Based on: Multiple Sclerosis — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 28 October 2026; the tracker page is the live version.
Full trial data → The Multiple Sclerosis pipeline page on the Research Tracker has every candidate, gene target and trial, with evidence grades.
Short answer: as of October 2026, the OSMF Research Tracker lists 48 candidate medicines for multiple sclerosis that are either approved medicines or have at least one registered clinical trial, built on 10 druggable gene targets, with 15 recent trials on ClinicalTrials.gov. 17 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Interferon beta-1b (Betaseron, BAY86-5046) — 4 registered trials · in clinical trials · NCT00787657 NCT00963833 NCT01436838
- Rebif® — 2 registered trials · in clinical trials · NCT02064816
- Ocrelizumab — 1 registered trial · approved medicine · NCT03025269
- Ofatumumab — 1 registered trial · approved medicine · NCT04353492
- ACTH — 1 registered trial · in clinical trials · NCT02315872
- Anti-Mullerian hormone (AMH) level — 1 registered trial · in clinical trials · NCT05754593
- cetrizine — 1 registered trial · in clinical trials · NCT04175834
- Dietary supplement intervention Goodphyte IB Defense — 1 registered trial · in clinical trials · NCT07380022
- Dietary supplement intervention Goodphyte Immunity — 1 registered trial · in clinical trials · NCT07380022
- diphenhydramine — 1 registered trial · in clinical trials · NCT04175834
- Disease-Modifying Therapies (DMTs) — 1 registered trial · in clinical trials · NCT06796504
- Early Harvest Extra Virgin Olive Oil — 1 registered trial · in clinical trials · NCT04120675
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in multiple sclerosis and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: BTK, CD52, IL2RA, ITGA4, LINGO1, MBP, MOG, MS4A1, S1PR1, VDR.
Which trials are registered?
Drug and biologic treatment trials whose main condition is multiple sclerosis, from the tracker's ClinicalTrials.gov snapshot. Full trial data →
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis NCT05269004 · Active Not Recruiting · Phase 3 · started 2022-05-03
- An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment NCT06675955 · Recruiting · Phase 3 · started 2024-12-13
- A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis NCT07067463 · Recruiting · Phase 3 · started 2026-03-23
- Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group NCT05754593 · Recruiting · started 2023-12-04
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis NCT07299019 · Recruiting · Phase 3 · started 2026-03-23
- A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity NCT06782490 · Recruiting · Phase 2 · started 2025-06-05
- A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) NCT07503873 · Recruiting · Phase 2 · started 2026-04-01
- Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. NCT06846281 · Recruiting · Phase 3 · started 2025-06-23
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) NCT07211633 · Active Not Recruiting · Phase 3 · started 2025-07-09
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab NCT05877963 · Recruiting · Phase 3 · started 2023-06-13
- The HIt HArd and hiT Early in Multiple Sclerosis Trial NCT07517185 · Recruiting · Phase 2 · started 2026-09-01
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) NCT04047628 · Recruiting · Phase 3 · started 2020-08-17
- Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for MS NCT05003388 · Recruiting · Phase 1 · started 2021-06-26
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) NCT03109288 · Recruiting · Phase 1/2 · started 2017-08-11
- Obe-cel in Refractory Progressive Forms of Multiple Sclerosis NCT07139743 · Recruiting · Phase 1 · started 2025-08-04
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The list is restricted to medicines and supplements: trial arms that are devices, procedures, behavioural programmes or measurements are filtered out automatically, so an occasional misclassified entry is possible; the tracker page lists every arm. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take. How sources are chosen, graded and corrected is set out in our editorial policy.
More Neurology notes
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 28 October 2026.